Inovio Pharmaceuticals (INO) Current Assets (2010 - 2026)

Inovio Pharmaceuticals has disclosed Current Assets across 17 years of filings, most recently posting $39.9 million for Q2 2026.

• In Q2 2026, Current Assets fell 24.26% year-over-year to $39.9 million; the TTM figure through Jun 2026 stood at $39.9 million (down 24.26% YoY), while the FY2025 annual figure was $61.1 million, down 37.52% from the prior year.
• Current Assets came in at $39.9 million for Q2 2026 at Inovio Pharmaceuticals, up from $39.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $416.2 million in Q2 2022 to a low of $39.4 million in Q1 2026.
• Average Current Assets over 5 years is $165.8 million, with a median of $114.6 million recorded in 2024.
• Year-over-year, Current Assets decreased 23.27% in 2022 and plunged 55.17% in 2025.
• Over 5 years, Current Assets stood at $315.2 million in 2022, then sank by 51.43% to $153.1 million in 2023, then plunged by 36.11% to $97.8 million in 2024, then tumbled by 37.52% to $61.1 million in 2025, then slumped by 34.7% to $39.9 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $39.9 million in Q2 2026, $39.4 million in Q1 2026, and $61.1 million in Q4 2025.